Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,386.52
(
-1.40%
)
US TECH 100
22,536.40
(
-1.81%
)
Dow Jones
45,274.91
(
-1.49%
)
Brent Oil
105.77
(
5.07%
)
Bitcoin
65,789.63
(
-4.35%
)
News Focus
News Focus
Post# of 257295
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

turtlepower

Send PM Follow Ignore
Followers 1
Posts 1114
Boards Moderated 0
Alias Born 04/07/2009

turtlepower

Re: caravon post# 149707

Monday, 10/01/2012 9:12:27 AM

Monday, October 01, 2012 9:12:27 AM

Post# of 257295

The PhII placebo-arm had just 6% of KRAS-mutant pts. These pts have just 2.5 months mOS in the 1st-line pts.



2.5M sounds a bit low. In the ARRY P2 trial 2nd line KRAS mutant patients had a mOS of 5.2 months.
http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-newsArticle&ID=1702337&highlight=
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today